Fredrik Schjesvold
Fredrik Schjesvold is an expert in Hematology at Oslo University Hospital (Norway). As of October 2026, ScienceLeadR ranks Fredrik Schjesvold in the top 1% of experts worldwide for Multiple Myeloma, Hemostatic Disorders and Paraproteinemias. Fredrik Schjesvold has authored 262 publications, the most recent in 2026, and is an investigator in 54 clinical trials, 17 of them ongoing. SLR score: 2,046 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology - Cardiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2008 - 2026
Number : 262
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial. PMID 42790445 — progression-free survival, dexamethasone, neoplasms, disease progression, bortezomib, drug-related side effects and adverse reactions, multiple myeloma, pneumonia, sepsis, therapeutics, infections | Lancet Oncol Top journal | 2026 | 1 |
| T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis. PMID 42844619 — cells, hematology, progression-free survival, probability, multiple myeloma, network meta-analysis, therapeutics, t-lymphocytes | J Hematol Oncol Top journal | 2026 | 0 |
| Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers. PMID 42581608 — zoledronic acid, hematology, bone remodeling, collagen, bone diseases, tartrate-resistant acid phosphatase, multiple myeloma, phosphoric monoester hydrolases, therapeutics | Br J Haematol | 2026 | 0 |
| Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients. PMID 42337226 — cells, leukemia, plasma cell, plasma cells, leukemia, transplants, plasma | Blood Cancer J | 2026 | 1 |
| The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN). PMID 42315477 — proteasome inhibitors, hematology, maintenance, multiple myeloma, network meta-analysis, lenalidomide, transplants, proteasome endopeptidase complex, therapeutics | Am J Hematol | 2026 | 0 |
Clinical Studies 54
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
17 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study to Investigate the Efficacy Safety and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion 10 ) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving BCMA CD3 Directed Bispecific Antibody Therapy 2024-518420-80-00 — cells, cd3 complex, safety, sudden infant death, immunoglobulins, multiple myeloma, b-cell maturation antigen, therapeutics, globulins, b-lymphocytes, infections | Phase 3 | Recruiting | 2026 |
| Phase 3 Study to Evaluate Mezigdomide (CC 92480 BMS 986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma SUCCESSOR 2 2022-500861-29-00 — dexamethasone, multiple myeloma | Phase 3 | Active not recruiting | 2023 |
| Phase 1b 2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and or Refractory Multiple Myeloma 2025-522090-11-00 — safety, multiple myeloma | Phase 1/Phase 2 | Recruiting | 2026 |
| A phase 1 phase 2 study to investigate safety tolerability and efficacy with TG01 QS 21 vaccine administration in patients with confirmed KRAS or NRAS codon 12 13 mutation and high risk smoldering multiple myeloma or multiple myeloma and evidence of measurable disease 1 line of treatment 2022-502275-39-00 — safety, vaccines, codon, multiple myeloma, therapeutics, mutation, smoldering multiple myeloma | Phase 1/Phase 2 | Recruiting | 2023 |
| Phase 1b 2a Study to Evaluate CC 92480 (BMS 986348) in Combination with Other Treatments in Relapsed or Refractory Multiple Myeloma 2023-509384-25-00 — safety, multiple myeloma, therapeutics, pharmacokinetics | Phase 1/Phase 2 | Recruiting | 2022 |
LeadR Networks
Main global connection map